158 related articles for article (PubMed ID: 33388995)
1. Associations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer.
Suárez GM; Añé-Kourí AL; González A; Lorenzo-Luaces P; Neninger E; Salomón EE; Cordero L; Catalá M; Ledón N; Pereira K; Sánchez MG; García B; Crombet T; Mazorra Z; Saavedra D; Lage A
Cancer Immunol Immunother; 2021 Jun; 70(6):1735-1743. PubMed ID: 33388995
[TBL] [Abstract][Full Text] [Related]
2. Identifying predictive biomarkers of CIMAvaxEGF success in non-small cell lung cancer patients.
Lorenzo-Luaces P; Sanchez L; Saavedra D; Crombet T; Van der Elst W; Alonso A; Molenberghs G; Lage A
BMC Cancer; 2020 Aug; 20(1):772. PubMed ID: 32807114
[TBL] [Abstract][Full Text] [Related]
3. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients.
Saavedra D; García B; Lorenzo-Luaces P; González A; Popa X; Fuentes KP; Mazorra Z; Crombet T; Neninger E; Lage A
Cancer Immunol Immunother; 2016 Jan; 65(1):37-45. PubMed ID: 26589409
[TBL] [Abstract][Full Text] [Related]
5. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
[TBL] [Abstract][Full Text] [Related]
6. Impact of Lymphocyte Subsets on Chemotherapy Efficacy and Long-term Survival of Patients with Advanced Non-small-cell Lung Cancer.
Wei Z; Zhang W; Gao F; Wu Y; Zhang G; Liu Z; Jiao S
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Jun; 39(3):371-376. PubMed ID: 28695808
[TBL] [Abstract][Full Text] [Related]
7. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Effect of Lentinan on Aberrant T Subsets and Cytokines Profile in Non-small Cell Lung Cancer Patients.
Wang XE; Wang YH; Zhou Q; Peng M; Zhang J; Chen M; Ma LJ; Xie GM
Pathol Oncol Res; 2020 Jan; 26(1):499-505. PubMed ID: 30460541
[TBL] [Abstract][Full Text] [Related]
9. Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy.
Suárez GM; Catalá M; Peña Y; Portela S; Añé-Kourí AL; González A; Lorenzo-Luaces P; Díaz M; Molina MLA; Pereira K; Hernández JC; Ramos R; Reyes MC; Ledón N; Mazorra Z; Crombet T; Lage A; Saavedra D
Front Oncol; 2022; 12():823287. PubMed ID: 35155258
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
Rice SJ; Belani CP
PLoS One; 2021; 16(12):e0260988. PubMed ID: 34855926
[TBL] [Abstract][Full Text] [Related]
13. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies.
McCoy MJ; Lake RA; van der Most RG; Dick IM; Nowak AK
Br J Cancer; 2012 Sep; 107(7):1107-15. PubMed ID: 22910319
[TBL] [Abstract][Full Text] [Related]
14. The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.
Zhuo M; Chen H; Zhang T; Yang X; Zhong J; Wang Y; An T; Wu M; Wang Z; Huang J; Zhao J
Cancer Biomark; 2018; 22(3):467-476. PubMed ID: 29758930
[TBL] [Abstract][Full Text] [Related]
15. Disturbed Th17/Treg Balance in Patients with Non-small Cell Lung Cancer.
Duan MC; Han W; Jin PW; Wei YP; Wei Q; Zhang LM; Li JC
Inflammation; 2015 Dec; 38(6):2156-65. PubMed ID: 26077695
[TBL] [Abstract][Full Text] [Related]
16. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
17. [Circulating lymphocyte subsets in patients with lung cancer and their prognostic value].
Luo J; Ling Z; Mao W
Zhongguo Fei Ai Za Zhi; 2011 Aug; 14(8):669-73. PubMed ID: 21859548
[TBL] [Abstract][Full Text] [Related]
18. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD1 and BTLA on the CD8
Bao Y; Mo JF; Wu JY; Cao CX
Chin Med Sci J; 2019 Nov; 34(4):248-255. PubMed ID: 33906710
[No Abstract] [Full Text] [Related]
20. CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.
Karagöz B; Bilgi O; Gümüs M; Erikçi AA; Sayan O; Türken O; Kandemir EG; Oztürk A; Yaylaci M
Med Oncol; 2010 Mar; 27(1):29-33. PubMed ID: 19148592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
